DrugsControl Media Services
DrugsControl.org

News Detail

Avoid piperacillin-tazobactam when treating BSI cause by ceftriaxone-resistant pathogens (22-04-2018)

Madrid, Spain, 21 April 2018: The antibiotic combination treatment piperacillin-tazobactam was significantly less effective than meropenem when treating potentially fatal bloodstream infections (BSI) caused by ceftriaxone-resistant Escherichia coli and  View Details

Source : EurekAlert

Related News